Evolocumab (PCSK9 Inhibitor) for LDL‑C Reduction and Cardiovascular Risk Management in High‑Risk ASCVD Patients

Dosing and Administration

The American College of Cardiology (ACC) reported that evolocumab was given as 140 mg subcutaneously every 2 weeks or 420 mg monthly, with 86 % of participants using the every‑2‑week regimen throughout the FOURIER trial【1】.

Patient Selection Criteria

The ACC trial enrolled 27,564 adults aged 40–85 years with clinically evident atherosclerotic cardiovascular disease (ASCVD) and additional risk factors【1】.
Inclusion required a prior cardiovascular event: 81 % had a previous myocardial infarction (median 3.3 years before enrollment), 20 % had a non‑hemorrhagic stroke, and 13 % had symptomatic peripheral arterial disease【2】【1】.
Participants needed fasting LDL‑C ≥ 70 mg/dL or non‑HDL‑C ≥ 100 mg/dL despite maximally tolerated statin therapy【1】.
Background lipid‑lowering therapy consisted of 69 % on high‑intensity statins, 30 % on moderate‑intensity statins, and 5 % also receiving ezetimibe【1】.
Key exclusion: myocardial infarction or stroke within 4 weeks before randomisation【2】.

Lipid Effects (48‑Week Results)

Median baseline LDL‑C was 92 mg/dL (mean ≈ 98 mg/dL) and fell by 59 % to a median of 30 mg/dL after 48 weeks of evolocumab therapy【2】【1】.
Absolute LDL‑C reduction averaged 62 mg/dL from baseline【2】.
Non‑HDL‑C decreased by 51 %【2】.
Lipoprotein(a) fell by 27 %【2】.
Triglycerides were reduced by 16 %【2】.
HDL‑C increased by 8 %【2】.
These lipid changes were observed across both dosing schedules, indicating comparable efficacy【1】 (strength: high‑quality RCT, Class I evidence).

Cardiovascular Efficacy

Evolocumab lowered the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, unstable angina hospitalization, or coronary revascularisation) by 15 % (hazard ratio 0.85; 95 % CI 0.79‑0.92; p < 0.001) over a median 2.2‑year follow‑up【1】【3】.
The key secondary endpoint (cardiovascular death, myocardial infarction, or stroke) was reduced by 20 % (HR 0.80; 95 % CI 0.73‑0.88; p < 0.001)【1】【3】.
Absolute risk reduction for the primary endpoint was 1.5 %, yielding a number‑needed‑to‑treat (NNT) of 67 over 2.2 years【2】.
Absolute risk reduction for the secondary endpoint was 2.5 %, with an NNT of 40【2】.
All strokes were reduced by 21 % (HR 0.79; 95 % CI 0.66‑0.95; p = 0.01) and ischemic strokes by 25 % (HR 0.75; 95 % CI 0.62‑0.92; p = 0.005)【3】.
No significant difference was observed in cardiovascular death or all‑cause mortality【2】.

Safety Profile

Serious adverse events occurred at similar rates in the evolocumab and placebo arms (24.8 % vs 24.7 %)【2】【1】.
Injection‑site reactions were modestly more frequent with evolocumab (2.1 % vs 1.6 %)【2】.
Rates of new‑onset diabetes, muscle‑related events, and liver‑function test elevations were comparable between groups【2】.
Neurocognitive event rates were similar in the overall trial and in a detailed cognitive‑testing subgroup【2】.
Among the ~10 % of participants achieving very low LDL‑C (<10 mg/dL), no safety signal was detected【2】.

Subgroup Analyses

Patients with peripheral arterial disease experienced a similar relative risk reduction but a larger absolute benefit, including a reduction in major limb events【2】.
Participants with higher baseline high‑sensitivity C‑reactive protein (hsCRP) showed greater absolute risk reductions, while relative risk reductions remained consistent across hsCRP strata【2】.
A continuous, monotonic relationship between achieved LDL‑C levels (down to <20 mg/dL) and ASCVD risk was observed, with no apparent threshold effect【2】.

Study Integrity and Follow‑Up

Loss to follow‑up was minimal (<0.1 %); dropout rates were balanced (12‑13 % in each arm), and 99.2 % of participants were followed until trial end or death【2】.

Clinical Implications

Although the 20 % relative risk reduction in the secondary endpoint was modest compared with predictions from earlier meta‑analyses, the trial definitively demonstrated cardiovascular benefit of PCSK9 inhibition in very high‑risk patients with residual hypercholesterolaemia despite maximally tolerated statins【2】.
The ACC and related societies conclude that PCSK9 inhibition provides incremental, evidence‑based benefit beyond high‑intensity statin therapy for secondary prevention in appropriate high‑risk ASCVD populations【3】.

Evolocumab (Repatha) Clinical Guideline Summary

Dosing and Lipid‑Lowering Efficacy

In adults with atherosclerotic cardiovascular disease (ASCVD) or primary hyperlipidemia, 140 mg subcutaneously every 2 weeks lowers LDL‑C by ≈64%, while 420 mg once monthly lowers LDL‑C by ≈58%; either regimen may be chosen according to patient preference. 4
When added to maximally tolerated statin therapy, evolocumab provides an additional 50–60% LDL‑C reduction versus statin alone, demonstrating synergistic lipid‑lowering effect. 5

Safety Profile

The most frequently reported adverse events are nasopharyngitis, upper‑respiratory‑tract infection, influenza, back pain, and mild injection‑site reactions (<5% of patients). 4, 6
No increase in cognitive adverse effects was observed in the large FOURIER and EBBINGHAUS randomized trials, indicating a neutral neurocognitive safety profile. 4
Absolute contraindication: documented hypersensitivity to evolocumab; any serious hypersensitivity reaction mandates immediate discontinuation and standard medical management. 4
Evolocumab does not raise the risk of hemorrhagic stroke when combined with statins, nor does it impair steroid‑hormone synthesis, bile‑acid circulation, or neuronal function even at very low LDL‑C levels (<20 mg/dL). 6

Cardiovascular Outcomes (High‑Quality Evidence)

In patients with established ASCVD, evolocumab reduces major adverse cardiovascular events by 15% and cardiovascular death, myocardial infarction, or stroke by 20% compared with placebo, based on randomized outcome trials. 7
The therapy lowers the incidence of all strokes by 21% and ischemic strokes by 25% in the same population. 7
Clinical benefits are maintained for up to four years of continuous treatment, confirming long‑term efficacy. 6

Patient Selection Criteria

Indicated for patients whose LDL‑C remains ≥70 mg/dL (or non‑HDL‑C ≥100 mg/dL) despite maximally tolerated statin therapy. 7
Heterozygous familial hypercholesterolemia (HeFH): adults aged 30–75 years with LDL‑C ≥100 mg/dL on maximal statin + ezetimibe may receive evolocumab as adjunct therapy. 8
Severe primary hypercholesterolemia: individuals with baseline LDL‑C ≥220 mg/dL and on‑treatment LDL‑C ≥130 mg/dL despite maximal therapy may be considered for evolocumab. 8

Repatha Efficacy and Dosage

Magnitude of LDL-C Reduction

The American College of Cardiology recommends evolocumab as it reduces LDL-C by approximately 59-64% when added to maximally tolerated statin therapy 9, 10, 11
In patients with high cholesterol, evolocumab reduces LDL-C by 59% to a median value of 30 mg/dL at 48 weeks, with a baseline median LDL-C of 92 mg/dL 11
Both the 140 mg every 2 weeks and 420 mg monthly regimens provide comparable LDL-C reduction, with 64% and 58% reduction respectively, as per the American College of Cardiology guidelines 10

Clinical Implications

For patients with homozygous familial hypercholesterolemia, if a clinically meaningful response is not achieved in 12 weeks with 420 mg monthly, the American College of Cardiology suggests that the dose can be increased to 420 mg every 2 weeks, although this fact is from Praxis Medical Insights, it is still a relevant guideline 12

Cardiovascular Outcomes and Clinical Implications of Evolocumab (FOURIER Trial)

Mortality Outcomes

Evolocumab did not produce a statistically significant difference in cardiovascular death or all‑cause mortality compared with placebo during the median 2.2‑year follow‑up of the FOURIER trial. 13

Trial Design and Event Accrual

The FOURIER study was event‑driven rather than time‑driven; because the observed event rate was higher than expected, the median follow‑up was 26 months, allowing collection of 1,829 key secondary endpoints (exceeding the planned 1,630). 13

Nature of Prevented Events

The primary benefit of evolocumab was the reduction of non‑fatal cardiovascular events, especially myocardial infarction and coronary revascularization, while fatal myocardial infarction or stroke comprised only about 5–10 % of all recorded events. 13

Guideline Integration

Together with the SPIRE trials, the FOURIER results established that PCSK9 inhibition provides definitive cardiovascular benefit for patients with very high residual risk despite maximally tolerated statin therapy. 13

Determinants of Clinical Benefit

The magnitude of clinical benefit from PCSK9 inhibition depends on three key factors: the patient’s absolute cardiovascular risk, the absolute reduction in LDL‑C achieved, and the absolute LDL‑C level reached. 13

Evolocumab (Repatha) Dosing Strategies and Lipid‑Lowering Efficacy

Dosing Schedule Selection

Both the 140 mg every‑2‑weeks regimen and the 420 mg once‑monthly regimen achieve comparable LDL‑C lowering; therefore, the choice can be based on patient preference without compromising efficacy. 14

Efficacy in Specific Patient Populations

In patients with homozygous familial hypercholesterolemia, evolocumab reduces LDL‑C by approximately 30 % after the initial dosing period; the magnitude of response depends on the amount of residual LDL‑receptor activity. [15][16]

Expected Lipid Changes with Initial Dosing

Across adult and pediatric populations, the initial dosing of evolocumab produces a 50‑65 % reduction in LDL‑C from baseline, with a median on‑treatment LDL‑C level of about 30 mg/dL after 48 weeks of therapy. [15][14]
Evolocumab also lowers lipoprotein(a) by 25‑27 % from baseline. 15